<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of sweating in palliative care</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of sweating in palliative care</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of sweating in palliative care</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shalini Dalal, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph A Arthur, MD, FAAHPM</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eduardo Bruera, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas J Smith, MD, FACP, FASCO, FAAHPM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2423363580"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sweating is the body’s normal mechanism to maintain optimal physiologic temperature. When the body’s internal temperature rises beyond the normal range, sweating occurs to allow the body to cool and return to normal physiologic temperature. Hyperhidrosis is defined as inappropriately excessive sweating beyond what is required for thermoregulatory needs and environmental conditions. It is often described as night sweats or nocturnal diaphoresis when it occurs at night (see  <a class="medical medical_review" href="/z/d/html/2768.html" rel="external">"Evaluation of the patient with night sweats or generalized hyperhidrosis", section on 'Definitions'</a>). This topic will review the clinical presentation, assessment and management of sweating in the palliative care population.</p><p class="headingAnchor" id="H2103609189"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Hyperhidrosis can be categorized as primary or secondary. Primary, or idiopathic, hyperhidrosis affects approximately 3 percent of the population, usually begins around puberty or earlier, and has a strong genetic predisposition. It is usually localized to areas with high eccrine sweat glands, such as the axilla, palms, and soles of the feet (and, less commonly, the head and face). (See  <a class="medical medical_review" href="/z/d/html/5567.html" rel="external">"Primary focal hyperhidrosis"</a>.)</p><p>By contrast, secondary hyperhidrosis can accompany a variety of conditions that fall under the categories of endocrine, metabolic, or neurologic disorders; tumors; infections and other febrile illnesses; or medication use. It is usually generalized (rather than focal), and may be present exclusively at night (see <a class="local">'Generalized'</a> below and <a class="local">'Focal'</a> below). It is more difficult to treat than localized primary hyperhidrosis. The main causes of secondary hyperhidrosis in palliative care populations are outlined in the table  (<a class="graphic graphic_table graphicRef115342" href="/z/d/graphic/115342.html" rel="external">table 1</a>).</p><p>Hyperhidrosis can also be classified as generalized or focal. (See <a class="local">'Generalized'</a> below and <a class="local">'Focal'</a> below.)</p><p class="headingAnchor" id="H774597789"><span class="h1">PREVALENCE</span><span class="headingEndMark"> — </span>Hyperhidrosis generally affects about 3 to 4 percent of people in the United States [<a href="#rid1">1,2</a>]. However, the prevalence in palliative care populations, including those with advanced cancer, ranges from 5 to 28 percent [<a href="#rid3">3,4</a>]. For example, night sweats are especially common in patients with Hodgkin lymphoma, manifesting in 25 percent of patients as an early symptom; night sweats are one of the “B” symptoms used for staging classification. (See  <a class="medical medical_review" href="/z/d/html/4748.html" rel="external">"Pretreatment evaluation, staging, and treatment stratification of classic Hodgkin lymphoma", section on 'B symptoms'</a>.)</p><p class="headingAnchor" id="H1742218569"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The majority of sweat glands in the body are eccrine glands. These are distributed throughout the body surface, predominantly in the palmar, plantar, axillary, and craniofacial regions, and they are innervated by the sympathetic nervous system. The main neurotransmitter of the neuroglandular junction of the sympathetic fibers is acetylcholine, unlike in most other sympathetic nerve terminals, whose neurotransmitter is noradrenaline. Acetylcholine normally binds to muscarinic receptors in eccrine sweat glands to induce sweating as a physiologic response to core body temperature control during times of physical or psychological stress [<a href="#rid5">5</a>]. In hyperhidrosis, there is hyperactivity of the sympathetic nervous system which results in excessive release of acetylcholine from the nerve ending and an impairment of the negative feedback mechanism to the hypothalamus. This causes the body to sweat more than what is required to cool down the body's temperature [<a href="#rid6">6,7</a>].</p><p>It is also believed that, specifically in axillary hyperhidrosis, there is an abnormal regeneration of sympathetic nerves or an increase in the number and/or distribution of eccrine glands due to hyperstimulation [<a href="#rid8">8</a>]. This finding is not identified in palmar hyperhidrosis.</p><p class="headingAnchor" id="H420921133"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The etiology of primary hyperhidrosis appears unclear but genetic factors are believed to play a role [<a href="#rid8">8</a>]. The causes of secondary hyperhidrosis are relatively easier to characterize because they usually accompany a variety of conditions that fall under the general categories of endocrine, metabolic, neurologic, or psychiatric disorders; tumors; febrile illnesses (including infection); or medication use. The main causes of secondary hyperhidrosis in palliative care populations are outlined in the table  (<a class="graphic graphic_table graphicRef115342" href="/z/d/graphic/115342.html" rel="external">table 1</a>). A more comprehensive discussion of the differential diagnosis of night sweats is available elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2768.html" rel="external">"Evaluation of the patient with night sweats or generalized hyperhidrosis"</a>.)</p><p class="headingAnchor" id="H1919738499"><span class="h2">Generalized</span></p><p class="headingAnchor" id="H3291461003"><span class="h3">Cancer patients</span><span class="headingEndMark"> — </span>Among palliative care patients with cancer, generalized sweating may be tumor or treatment related. However, hyperhidrosis in palliative care patients can be multifactorial (eg, both liver metastases and withdrawal from opioids).</p><p class="bulletIndent1"><span class="glyph">●</span>Sweating may be commonly experienced by patients with breast and prostate cancer, but this is more commonly attributed to treatment rather than the disease itself (eg, vasomotor symptoms associated with treatments that result in estrogen or androgen deficiency [selective estrogen receptor modulators, aromatase inhibitors, and androgen deprivation therapy]). (See  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer", section on 'Side effects'</a> and  <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy", section on 'Vasomotor symptoms'</a> and  <a class="medical medical_review" href="/z/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with Hodgkin lymphoma and non-Hodgkin lymphoma may report fever and/or night sweats as early constitutional symptoms. In either case, the pathophysiology underlying the development of night sweats is not known. (See  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma", section on 'Systemic "B" symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Less commonly, leukemia and multiple myeloma may be associated with fever and night sweats.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with nonhematologic malignancies may also experience night sweats, sometimes attributed to tumor-related fever or flushing. Malignancy is one of the most common causes of fever of unknown origin. (See  <a class="medical medical_review" href="/z/d/html/2737.html" rel="external">"Fever of unknown origin in adults: Etiologies", section on 'Malignancies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reports exist of night sweats among patients with most types of solid tumors, but this is most common with renal cell cancer and primary liver cancers such as cholangiocarcinoma. Other solid tumors metastatic to the liver can also cause fever and night sweats, but this is uncommon overall and typically associated with a bulky, treatment-refractory tumor [<a href="#rid9">9</a>]. The pathophysiology is unclear. (See  <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">"Clinical manifestations, evaluation, and staging of renal cell carcinoma", section on 'Fever'</a> and  <a class="medical medical_review" href="/z/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts", section on 'Metastatic tumors'</a> and  <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Other clinical presentations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Advanced medullary carcinoma of the thyroid may cause flushing due to calcitonin secretion. (See  <a class="medical medical_review" href="/z/d/html/7848.html" rel="external">"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging", section on 'Clinical presentation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Insulinomas may cause night sweats because of nocturnal hypoglycemia. (See  <a class="medical medical_review" href="/z/d/html/2187.html" rel="external">"Insulinoma", section on 'Clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vasoactive intestinal polypeptide (VIP)-secreting tumors can also cause sweats. (See  <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">"VIPoma: Clinical manifestations, diagnosis, and management", section on 'Clinical manifestations'</a>.) </p><p></p><p class="headingAnchor" id="H2576161107"><span class="h3">Other causes</span><span class="headingEndMark"> — </span>Infectious, neurologic, endocrine, and medication-related etiologies for generalized night sweats are discussed in detail elsewhere. A list of medications associated with sweating is provided in the table  (<a class="graphic graphic_table graphicRef56351" href="/z/d/graphic/56351.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/2768.html" rel="external">"Evaluation of the patient with night sweats or generalized hyperhidrosis"</a>.)</p><p class="headingAnchor" id="H1750770995"><span class="h2">Focal</span><span class="headingEndMark"> — </span>Secondary focal hyperhidrosis can be associated with peripheral neuropathies, such as with diabetic neuropathy or complex regional pain syndrome (CRPS) [<a href="#rid10">10,11</a>]. In the former, sweating may disappear with progression of neuropathy secondary to nerve damage. In CRPS, pain is usually severe and predominant, and it can be debilitating. Post-stroke unilateral hyperhidrosis has been observed following lesions to the cerebrum, hypothalamus and midbrain, and spinal cord [<a href="#rid12">12-22</a>], which is partly due to the disruption of inhibitory neural signals that regulate sweating contralateral to the lesion.</p><p class="headingAnchor" id="H3090253812"><span class="h1">CLINICAL PRESENTATION AND ASSESSMENT</span><span class="headingEndMark"> — </span>Most advanced cancer patients with hyperhidrosis describe symptoms as nocturnal (night sweats) and of moderate to severe intensity [<a href="#rid23">23-25</a>]. Night sweats may be associated with the need to change clothes or sheets (drenching sweats).</p><p>Initial assessment should include a detailed history, medication review, symptom assessment, and physical examination, which all help reveal the location and severity of hyperhidrosis and provide clues to the possible underlying etiology.</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are younger, have a family history of the disorder, present with a chronic onset of more than six months, and have bilateral involvement usually have primary hyperhidrosis. Symptoms that present later in life are more likely of a secondary cause [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specific symptoms that should be sought include pain, weight loss, anxiety, jitteriness, flushing, sleep disruption, signs and symptoms of autonomic neuropathy, and fever and other symptoms/signs suggestive of infection.</p><p></p><p>The severity of hyperhidrosis may be assessed by the impact on functioning, social interactions, sleep, and the need to change clothes and bed linens. A number of objective hyperhidrosis assessment scales [<a href="#rid26">26</a>] are available and are mainly used for focal hyperhidrosis; they are generally not relevant in the palliative care setting.</p><p>Further diagnostic workup (ie, laboratory evaluation and diagnostic radiographic imaging), especially if fever is found, depends on the clinical context and goals of care.</p><p class="headingAnchor" id="H2760472237"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3725853139"><span class="h2">General principles and nonpharmacologic measures</span><span class="headingEndMark"> — </span>Hyperhidrosis in palliative care patients is predominantly secondary in nature and its treatment can be challenging for both the patient and the clinician. The first steps in management should involve treatment of the underlying etiology, if clinically appropriate, such as infections or hyperthyroidism. A medication review is appropriate  (<a class="graphic graphic_table graphicRef56351" href="/z/d/graphic/56351.html" rel="external">table 2</a>), and if a patient is taking a medication known to cause flushing or excessive sweating, the medication should be withdrawn, if possible, as a diagnostic trial. If this is not possible, changing to a lower dose, an extended-release formulation of the medication, or a drug less likely to cause sweating is another potential strategy.</p><p>Nonpharmacologic treatment approaches to symptom management include use of fans to keep the skin cool, wearing loose cotton clothing, use of cotton bed linens, and maintaining adequate hydration, along with emotional support and reassurance. In one study among men with prostate cancer, cognitive-behavioral therapy reduced hot flashes with paced breathing and relaxation, among other measures [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H183941015"><span class="h2">Pharmacologic measures</span></p><p class="headingAnchor" id="H999002422"><span class="h3">Generalized symptoms by etiology</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – If infection is suspected due to fever, and the goals of care are not consistent with a formal diagnostic workup, an empiric seven-day course of antibiotics such as <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> 500 mg daily, or, in the case of suspected severe infection, standard broad-spectrum agents such as <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> 2 g intravenous (IV) every eight hours or <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> 500 mg IV every six hours may be reasonable. If more aggressive care is indicated, basic infectious workup including a complete blood count, urinalysis, blood cultures, and chest radiograph may be initiated. More detailed infectious workup is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2768.html" rel="external">"Evaluation of the patient with night sweats or generalized hyperhidrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor-associated</strong> – If tumor-associated fever is suspected, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> or nonsteroidal antiinflammatory drugs (NSAIDs) are initially used. A randomized trial of three oral NSAIDs in 48 patients with tumor-related fever showed comparable efficacy for <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a>, <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a> sodium, and <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a>, although naproxen provided the most rapid response [<a href="#rid28">28</a>]. Although less effective than NSAIDs, a trial of glucocorticoid such as <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 to 150 mg daily for two or more days may be considered in refractory cases, if it is not contraindicated [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes</strong> – For all other causes, NSAIDs are usually first-line treatment, followed by glucocorticoids for refractory symptoms as described above. Other options reported to be potentially effective may include <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">cimetidine</a> 400 to 800 mg once daily [<a href="#rid26">26</a>], <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> 5 mg twice daily [<a href="#rid30">30</a>], <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">oxybutynin</a> 5 mg at bedtime [<a href="#rid31">31</a>], and <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> at a starting dose of 100 mg three times daily [<a href="#rid32">32</a>]. Night sweats have also been shown to improve with use of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> given at 100 mg daily; however, its use is limited by side effects including painful, sometimes irreversible peripheral neuropathy, teratogenicity, and somnolence [<a href="#rid33">33-35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasomotor symptoms</strong> – Hyperhidrosis because of vasomotor symptoms (ie, hot flashes) typically presents as intermittent episodes of sudden heat sensation beginning on the upper chest and face that rapidly becomes generalized with profuse sweating. It is sometimes associated with palpitations, chills, shivering, and a feeling of anxiety. Among palliative care patients, it may either occur in postmenopausal women or in women who experience a “premature menopause” as a result of surgery and/or chemotherapy, or among hormone-related cancer patients such as breast, prostate, and endometrial cancer populations. Treatment approaches are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7390.html" rel="external">"Menopausal hot flashes"</a>.)</p><p></p><p class="headingAnchor" id="H2545170687"><span class="h3">Focal symptoms</span><span class="headingEndMark"> — </span>Most of the treatments described below are used for primary and localized hyperhidrosis and may therefore be rarely useful in palliative care patients, since the etiology in this patient population is predominantly secondary and generalized in nature. Oral anticholinergic agents may be of relatively more value and relevance in the palliative care patient population due to their generalized effects [<a href="#rid36">36,37</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical agents</strong> – Over-the-counter <a class="drug drug_general" data-topicid="8612" href="/z/d/drug information/8612.html" rel="external">aluminum chloride hexahydrate</a> has been used. It is best applied at night and washed off in the morning. Mild skin irritation can occur from its use [<a href="#rid7">7</a>]. <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">Glycopyrronium</a> tosylate topical cloth is also approved to treat excessive sweating [<a href="#rid6">6</a>]. Other topical agents include topical glycopyrrolate, topical <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">oxybutynin</a>, tannic acid, and potassium permanganate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral anticholinergic agents</strong> – For patients who do not respond to topical treatment or who have more generalized symptoms, oral anticholinergic agents such as oral <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">oxybutynin</a>, <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a>, <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">benztropine</a>, or <a class="drug drug_general" data-topicid="9823" href="/z/d/drug information/9823.html" rel="external">propantheline</a> bromide (where available) may be considered. Adverse effects such as dry eyes, dry mouth, urinary retention, and constipation can occur.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iontophoresis</strong> – This consists of passing a direct current across the skin with agents such as tap water or anticholinergics [<a href="#rid38">38</a>]. The mechanism of action is unclear. Tap water iontophoresis has a lower adherence rate because it is more time-consuming and less effective than anticholinergic iontophoresis, but it has a relatively safe side effect profile.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Botulinum toxin</strong> – Botulinum toxin A injection can be used for treatment of localized or regional hyperhidrosis in patients who do not respond to topical and oral medication therapy [<a href="#rid39">39</a>]. These injections are more expensive compared with topical and systemic medications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laser therapy</strong> – This is a relatively more recent treatment option for primary hyperhidrosis, especially in patients with unsuccessful results from topical and/or systemic treatments [<a href="#rid40">40</a>]. It functions by delivering energy to the tissue to damage the sweat glands, thereby reducing sweating. It is known to have a limited side effect profile which includes burns [<a href="#rid41">41</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical treatments</strong> – Surgical procedures such as sympathectomy, radiofrequency ablation, subcutaneous liposuction, and surgical excision of affected areas are used in refractory cases.</p><p></p><p class="headingAnchor" id="H2956041804"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119531.html" rel="external">"Society guideline links: Palliative care"</a>.)</p><p class="headingAnchor" id="H2429217567"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes </strong>– Secondary hyperhidrosis can accompany a variety of conditions, including endocrine, metabolic, neurologic, or psychiatric disorders; tumors; febrile illnesses (including infection); or medication use. The main causes of secondary hyperhidrosis in palliative care populations are outlined in the table  (<a class="graphic graphic_table graphicRef115342" href="/z/d/graphic/115342.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment </strong>–<strong> </strong>Initial assessment should include a history, medication review, symptom assessment and physical examination geared toward identifying possible etiologies and the severity of the hyperhidrosis. Further diagnostic workup, especially if fever is found, depends on the clinical scenario and goals of care. (See <a class="local">'Clinical presentation and assessment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General treatment principles </strong>–<strong> </strong>The first steps in management should involve treatment of the underlying etiology, if clinically appropriate and consistent with the goals of care, as well as elimination of any potential aggravating factors (eg, hyperthyroidism). If a patient is taking a medication known to cause flushing or excessive sweating, the medication should be withdrawn, if possible, as a diagnostic trial  (<a class="graphic graphic_table graphicRef56351" href="/z/d/graphic/56351.html" rel="external">table 2</a>). (See <a class="local">'General principles and nonpharmacologic measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific treatments</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonpharmacologic treatment approaches to management include the use of fans to keep the skin cool, wearing loose cotton clothing, the use of cotton bed linens, and maintaining adequate hydration. (See <a class="local">'General principles and nonpharmacologic measures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If infection is suspected and the goals of care are not consistent with a formal infectious workup, an empiric course of antibiotics is reasonable. (See <a class="local">'Generalized symptoms by etiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with suspected tumor-related fever and for those without fever, empiric treatment with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> or a nonsteroidal antiinflammatory drug (NSAID) is reasonable, followed by a glucocorticoid for refractory symptoms. (See <a class="local">'Generalized symptoms by etiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If sweating is a component of vasomotor symptoms (ie, hot flashes), treatment approaches may include megestrol, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, or antidepressants. (See <a class="local">'Generalized symptoms by etiology'</a> above and  <a class="medical medical_review" href="/z/d/html/7390.html" rel="external">"Menopausal hot flashes"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Focal symptoms can be treated with topical agents (eg, <a class="drug drug_general" data-topicid="8612" href="/z/d/drug information/8612.html" rel="external">aluminum chloride hexahydrate</a>), oral anticholinergics (eg, <a class="drug drug_general" data-topicid="9728" href="/z/d/drug information/9728.html" rel="external">oxybutynin</a>, <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">glycopyrrolate</a>, <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">benztropine</a>), botulinum toxin, and procedures such as iontophoresis and sympathectomy. (See <a class="local">'Focal symptoms'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 2004; 51:241.</a></li><li><a class="nounderline abstract_t">Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Etiology and clinical work-up. J Am Acad Dermatol 2019; 81:657.</a></li><li><a class="nounderline abstract_t">Mercadante S, Porzio G, Valle A, et al. Orphan symptoms in advanced cancer patients followed at home. Support Care Cancer 2013; 21:3525.</a></li><li><a class="nounderline abstract_t">Grond S, Zech D, Diefenbach C, Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 1994; 9:372.</a></li><li><a class="nounderline abstract_t">Shargall Y, Spratt E, Zeldin RA. Hyperhidrosis: what is it and why does it occur? Thorac Surg Clin 2008; 18:125.</a></li><li class="breakAll">Brackenrich J, Fagg C. Hyperhidrosis, StatPearls Publishing, 2020.</li><li><a class="nounderline abstract_t">Fujimoto T. Pathophysiology and Treatment of Hyperhidrosis. Curr Probl Dermatol 2016; 51:86.</a></li><li><a class="nounderline abstract_t">Sammons JE, Khachemoune A. Axillary hyperhidrosis: a focused review. J Dermatolog Treat 2017; 28:582.</a></li><li><a class="nounderline abstract_t">Toussaint E, Bahel-Ball E, Vekemans M, et al. Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer 2006; 14:763.</a></li><li><a class="nounderline abstract_t">Fealey RD, Low PA, Thomas JE. Thermoregulatory sweating abnormalities in diabetes mellitus. Mayo Clin Proc 1989; 64:617.</a></li><li><a class="nounderline abstract_t">Jänig W, Baron R. Complex regional pain syndrome is a disease of the central nervous system. Clin Auton Res 2002; 12:150.</a></li><li><a class="nounderline abstract_t">Labar DR, Mohr JP, Nichols FT 3rd, Tatemichi TK. Unilateral hyperhidrosis after cerebral infarction. Neurology 1988; 38:1679.</a></li><li><a class="nounderline abstract_t">Korpelainen JT, Sotaniemi KA, Myllylä VV. Asymmetric sweating in stroke: a prospective quantitative study of patients with hemispheral brain infarction. Neurology 1993; 43:1211.</a></li><li><a class="nounderline abstract_t">Kim BS, Kim YI, Lee KS. Contralateral hyperhidrosis after cerebral infarction. Clinicoanatomic correlations in five cases. Stroke 1995; 26:896.</a></li><li><a class="nounderline abstract_t">Smith CD. A hypothalamic stroke producing recurrent hemihyperhidrosis. Neurology 2001; 56:1394.</a></li><li><a class="nounderline abstract_t">Sakashita Y, Kakuta K, Kakuma K, Matsuda H. [Unilateral persistent hyperhidrosis after ischemic stroke]. Rinsho Shinkeigaku 1992; 32:454.</a></li><li><a class="nounderline abstract_t">Awada A, Ammar A, al-Rajeh S, Borollosi M. Excessive sweating: an uncommon sign of basilar artery occlusion. J Neurol Neurosurg Psychiatry 1991; 54:277.</a></li><li><a class="nounderline abstract_t">Mon Y, Mizotani M. [A case of hemi-hyperhidrosis and non-paralytic pontine exotropia due to brainstem infarction]. Rinsho Shinkeigaku 1992; 32:718.</a></li><li><a class="nounderline abstract_t">Iseri PK, Bayramgurler D, Koc K. Unilateral localized hyperhidrosis associated with frontal lobe meningioma. Neurology 2004; 63:1753.</a></li><li><a class="nounderline abstract_t">Pellecchia MT, Criscuolo C, De Joanna G, et al. Pure unilateral hyperhidrosis after pontine infarct. Neurology 2003; 61:1305.</a></li><li><a class="nounderline abstract_t">Korpelainen JT, Sotaniemi KA, Myllylä VV. Ipsilateral hypohidrosis in brain stem infarction. Stroke 1993; 24:100.</a></li><li><a class="nounderline abstract_t">Saito H, Sakuma H, Seno K. A case of traumatic high thoracic myelopathy presenting dissociated impairment of rostral sympathetic innervations and isolated segmental sweating on otherwise anhidrotic trunk. Tohoku J Exp Med 1999; 188:95.</a></li><li><a class="nounderline abstract_t">Ventafridda V, De Conno F, Ripamonti C, et al. Quality-of-life assessment during a palliative care programme. Ann Oncol 1990; 1:415.</a></li><li class="breakAll">Hanks GC. Oxford Textbook of Palliative Medicine, 4th ed, Oxford University Press, 2010.</li><li><a class="nounderline abstract_t">Quigley CS, Baines M. Descriptive epidemiology of sweating in a hospice population. J Palliat Care 1997; 13:22.</a></li><li class="breakAll">Pittelkow MR, Loprinzi CL, Pittelkow TP. Pruritus and sweating in palliative medicine. In: Oxford Textbook of Palliative Medicine, 5th ed, Cherny N, Fallon M, Kaasa S, et al (Eds), Oxford University Press, 2015. p.724.</li><li><a class="nounderline abstract_t">Stefanopoulou E, Yousaf O, Grunfeld EA, Hunter MS. A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN). Psychooncology 2015; 24:1159.</a></li><li><a class="nounderline abstract_t">Tsavaris N, Zinelis A, Karabelis A, et al. A randomized trial of the effect of three non-steroid anti-inflammatory agents in ameliorating cancer-induced fever. J Intern Med 1990; 228:451.</a></li><li><a class="nounderline abstract_t">Chang JC. Antipyretic effect of naproxen and corticosteroids on neoplastic fever. J Pain Symptom Manage 1988; 3:141.</a></li><li><a class="nounderline abstract_t">Zylicz Z, Krajnik M. Flushing and sweating in an advanced breast cancer patient relieved by olanzapine. J Pain Symptom Manage 2003; 25:494.</a></li><li><a class="nounderline abstract_t">Yarchoan M, Tucker W, Smith TJ. Successful Treatment of Neoplastic Fever with Oxybutynin. J Palliat Med 2019; 22:1491.</a></li><li><a class="nounderline abstract_t">Porzio G, Aielli F, Verna L, et al. Gabapentin in the treatment of severe sweating experienced by advanced cancer patients. Support Care Cancer 2006; 14:389.</a></li><li><a class="nounderline abstract_t">Calder K, Bruera E. Thalidomide for night sweats in patients with advanced cancer. Palliat Med 2000; 14:77.</a></li><li><a class="nounderline abstract_t">Deaner PB. The use of thalidomide in the management of severe sweating in patients with advanced malignancy: trial report. Palliat Med 2000; 14:429.</a></li><li><a class="nounderline abstract_t">Eisen TG. Thalidomide in solid tumors: the London experience. Oncology (Williston Park) 2000; 14:17.</a></li><li><a class="nounderline abstract_t">Henning MAS, Bouazzi D, Jemec GBE. Treatment of Hyperhidrosis: An Update. Am J Clin Dermatol 2022; 23:635.</a></li><li><a class="nounderline abstract_t">Brown AL, Gordon J, Hill S. Hyperhidrosis: review of recent advances and new therapeutic options for primary hyperhidrosis. Curr Opin Pediatr 2014; 26:460.</a></li><li><a class="nounderline abstract_t">Murphy R, Harrington CI. Treating hyperhidrosis. Iontophoresis should be tried before other treatments. BMJ 2000; 321:702.</a></li><li><a class="nounderline abstract_t">Al-Hashel JY, Youssry D, Rashaed HM, et al. Botulinum toxin A for palmar hyperhidrosis: assessment with sympathetic skin responses evoked by train of stimuli. Auton Autacoid Pharmacol 2016; 36:23.</a></li><li><a class="nounderline abstract_t">Cervantes J, Perper M, Eber AE, et al. Laser treatment of primary axillary hyperhidrosis: a review of the literature. Lasers Med Sci 2018; 33:675.</a></li><li><a class="nounderline abstract_t">Leclère FM, Moreno-Moraga J, Alcolea JM, et al. Efficacy and safety of laser therapy on axillary hyperhidrosis after one year follow-up: a randomized blinded controlled trial. Lasers Surg Med 2015; 47:173.</a></li></ol></div><div id="topicVersionRevision">Topic 129694 Version 4.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15280843" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30710604" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Etiology and clinical work-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24122405" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Orphan symptoms in advanced cancer patients followed at home.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7963790" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18557586" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hyperhidrosis: what is it and why does it occur?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18557586" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hyperhidrosis: what is it and why does it occur?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27584967" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pathophysiology and Treatment of Hyperhidrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28318360" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Axillary hyperhidrosis: a focused review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16528534" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Causes of fever in cancer patients (prospective study over 477 episodes).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2747292" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Thermoregulatory sweating abnormalities in diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12269546" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Complex regional pain syndrome is a disease of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3185901" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Unilateral hyperhidrosis after cerebral infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8170568" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Asymmetric sweating in stroke: a prospective quantitative study of patients with hemispheral brain infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7740586" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Contralateral hyperhidrosis after cerebral infarction. Clinicoanatomic correlations in five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11376196" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A hypothalamic stroke producing recurrent hemihyperhidrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1395337" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : [Unilateral persistent hyperhidrosis after ischemic stroke].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2030360" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Excessive sweating: an uncommon sign of basilar artery occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1291162" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : [A case of hemi-hyperhidrosis and non-paralytic pontine exotropia due to brainstem infarction].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534278" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Unilateral localized hyperhidrosis associated with frontal lobe meningioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14610150" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pure unilateral hyperhidrosis after pontine infarct.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418531" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ipsilateral hypohidrosis in brain stem infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10494905" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A case of traumatic high thoracic myelopathy presenting dissociated impairment of rostral sympathetic innervations and isolated segmental sweating on otherwise anhidrotic trunk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1707297" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Quality-of-life assessment during a palliative care programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1707297" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Quality-of-life assessment during a palliative care programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9105154" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Descriptive epidemiology of sweating in a hospice population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9105154" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Descriptive epidemiology of sweating in a hospice population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25753889" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2254714" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A randomized trial of the effect of three non-steroid anti-inflammatory agents in ameliorating cancer-induced fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3262142" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antipyretic effect of naproxen and corticosteroids on neoplastic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12782428" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Flushing and sweating in an advanced breast cancer patient relieved by olanzapine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31794374" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Successful Treatment of Neoplastic Fever with Oxybutynin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16402235" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Gabapentin in the treatment of severe sweating experienced by advanced cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10717731" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Thalidomide for night sweats in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11064791" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The use of thalidomide in the management of severe sweating in patients with advanced malignancy: trial report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11204668" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Thalidomide in solid tumors: the London experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35773437" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of Hyperhidrosis: An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24905102" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hyperhidrosis: review of recent advances and new therapeutic options for primary hyperhidrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11202931" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treating hyperhidrosis. Iontophoresis should be tried before other treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27878939" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Botulinum toxin A for palmar hyperhidrosis: assessment with sympathetic skin responses evoked by train of stimuli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29322402" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Laser treatment of primary axillary hyperhidrosis: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25663083" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy and safety of laser therapy on axillary hyperhidrosis after one year follow-up: a randomized blinded controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
